540
Participants
Start Date
April 30, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2028
Experimental dose: modified XELOX + sintilimab
The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
Standard dose: standard XELOX + sintilimab
The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
NOT_YET_RECRUITING
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
The Affliated Cancer Hospital of Guizhou Medical University, Guiyang
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
The Second Hospital of Dalian Medical University, Dalian
NOT_YET_RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
The Second Affiliated Hospital of Kunming Medical University, Kunming
Sun Yat-sen University
OTHER